Hopes that anti-tau drugs could join those targeting amyloid as treatments for Alzheimer's disease have been dented by the failure of a phase 2b trial of Johnson & Johnson's posdinemab. The AuTonomy ...

Alzheimer's disease is a neurodegenerative disease characterized by a progressive decline in mental functions and memory loss. Along with frontotemporal dementia and some other neurodegenerative ...

When Huawei unveiled its "Tau (τ) Scaling Law" at ISCAS 2026 in Shanghai, the announcement signalled more than another chip architecture update. It marked China's most ambitious attempt yet to ...

Macquarie's Eugene Hsiao discusses the end of Moore's Law after Huawei introduces Tau Scaling Law. He sees convergence of chipmaking paths as the race for more cutting-edge chips continue. Meanwhile, ...

For five decades, chipmakers chased Moore's Law by cramming smaller transistors onto silicon. That cadence has been slowing across the industry. For Huawei, it stopped entirely. He Tingbo said ...

Huawei is proposing a new way to keep the semiconductor industry moving forward at a time when making smaller and smaller chips is becoming increasingly difficult. At the International Circuit Systems ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...

A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting candidate missed its primary endpoint. But while the Alzheimer’s disease trial failed to yield the hoped-for dose-response data, ...

All processes such as wound healing, hair growth, and the replacement of old cells with new ones depend on cell division. During this process, chromosomes inside the cell must be evenly divided ...

In Alzheimer’s disease, two key proteins, extracellular amyloid-beta plaques and an intercellular protein called tau, disrupt communication between the brain’s cells and lead to cell damage and death.